Clinical Trial Update: Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan

View source ↗

Summary

A long-term real-world study of mepolizumab for eosinophilic granulomatosis with polyangiitis (Churg–Strauss) in Japan has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Nucala (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | Status: COMPLETED | Results posted: 2024-09-19